Literature DB >> 26914556

PSMA Expression in Papillary Thyroid Carcinoma: Opening a New Horizon in Management of Thyroid Cancer?

Sameer Kamalakar Taywade1, Nishikant Avinash Damle, Chandrasekhar Bal.   

Abstract

Prostate-specific membrane antigen (PSMA) is a type 2 transmembrane protein highly expressed in prostate cancer cells. We present the case of a 50-year-old man with metastatic papillary carcinoma of the thyroid, with rising thyroglobulin level and negative whole-body radioiodine scan after total thyroidectomy. Considering the limited treatment options available, it was decided to perform Ga-PSMA-HBED-CC PET/CT scan. It revealed intense radiotracer uptake in mediastinal and left supraclavicular lymph nodes, brain metastases, bilateral lung nodules, and skeletal sites. Patient also underwent F-FDG PET/CT. It demonstrated similar findings; however, the number of lesions detected in brain was less compared with Ga-PSMA PET/CT.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26914556     DOI： 10.1097/RLU.0000000000001148

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN： 0363-9762            Impact factor:   7.794


  21 in total

Review 1.  Molecular imaging of advanced thyroid cancer: iodinated radiotracers and beyond.

Authors:  Prasanna Santhanam; Lilja B Solnes; Steven P Rowe
Journal:  Med Oncol       Date:  2017-10-30       Impact factor: 3.064

2.  Well-Differentiated Thyroid Cancer Neovasculature Expresses Prostate-Specific Membrane Antigen-a Possible Novel Therapeutic Target.

Authors:  Maureen Moore; Suraj Panjwani; Rashmi Mathew; Michael Crowley; Yi-Fang Liu; Anna Aronova; Brendan Finnerty; Rasa Zarnegar; Thomas J Fahey; Theresa Scognamiglio
Journal:  Endocr Pathol       Date:  2017-12       Impact factor: 3.943

3.  Anaplastic thyroid carcinoma on 68 Ga-PSMA PET/CT: opening new frontiers.

Authors:  Nishikant Avinash Damle; Chandrasekhar Bal; Tejesh Pratap Singh; Ravikant Gupta; Sreenivasa Reddy; Rajeev Kumar; Madhavi Tripathi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-01-02       Impact factor: 9.236

4.  A new perspective for nuclear medicine: expanding the indications for PSMA targeted imaging and therapy.

Authors:  Frederik A Verburg; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-07-04       Impact factor: 9.236

Review 5.  Looking for Drugs in All the Wrong Places: Use of GCPII Inhibitors Outside the Brain.

Authors:  James J Vornov; Diane Peters; Mike Nedelcovych; Kristen Hollinger; Rana Rais; Barbara S Slusher
Journal:  Neurochem Res       Date:  2019-11-20       Impact factor: 3.996

6.  The prostate-specific membrane antigen (PSMA)-targeted radiotracer 18F-DCFPyL detects tumor neovasculature in metastatic, advanced, radioiodine-refractory, differentiated thyroid cancer.

Authors:  Prasanna Santhanam; Jonathon Russell; Lisa M Rooper; Paul W Ladenson; Martin G Pomper; Steven P Rowe
Journal:  Med Oncol       Date:  2020-10-09       Impact factor: 3.064

Review 7.  Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives.

Authors:  Philipp Backhaus; Benjamin Noto; Nemanja Avramovic; Lena Sophie Grubert; Sebastian Huss; Martin Bögemann; Lars Stegger; Matthias Weckesser; Michael Schäfers; Kambiz Rahbar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-01-15       Impact factor: 9.236

Review 8.  Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging.

Authors:  Sara Sheikhbahaei; Ali Afshar-Oromieh; Matthias Eiber; Lilja B Solnes; Mehrbod S Javadi; Ashley E Ross; Kenneth J Pienta; Mohamad E Allaf; Uwe Haberkorn; Martin G Pomper; Michael A Gorin; Steven P Rowe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-01       Impact factor: 9.236

9.  Incidental prostate-specific membrane antigen-avid glioblastoma detected on 68Ga-prostate-specific membrane antigen PET/CT.

Authors:  James Yuheng Jiang; Christine Kang; Paul Bui; Robert Mansberg
Journal:  Radiol Case Rep       Date:  2022-04-08

10.  PSMA expression by microvasculature of thyroid tumors - Potential implications for PSMA theranostics.

Authors:  Andrey Bychkov; Usanee Vutrapongwatana; Supatporn Tepmongkol; Somboon Keelawat
Journal:  Sci Rep       Date:  2017-07-12       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.